RXi Pharmaceuticals Corp. (RXII)

2.25
0.09 3.85
NASDAQ : Health Technology
Prev Close 2.34
Open 2.30
Day Low/High 2.25 / 2.35
52 Wk Low/High 1.90 / 7.70
Volume 41.27K
Avg Volume 369.20K
Exchange NASDAQ
Shares Outstanding 4.26M
Market Cap 9.70M
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals To Present An Update On Its Clinical And Cosmetic Dermatology Programs At The International Investigative Dermatology Conference

RXi Pharmaceuticals To Present An Update On Its Clinical And Cosmetic Dermatology Programs At The International Investigative Dermatology Conference

Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and the consumer testing program with its cosmetic product RXI-231 to improve the appearance of skin pigmentation.

Focused on Speculative Trading: RXII, BB, CASA

Focused on Speculative Trading: RXII, BB, CASA

We have this drifting action and uncorrelated action between stocks and the indices.

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

My biggest concern about the market continues to be a paucity of perky picks.

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

-- Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Stocks with insider trader activity include RXII, MA and SWN

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

Trade-Ideas LLC identified RXi Pharmaceuticals (RXII) as a strong on high relative volume candidate

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase™ 2013

RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase™ 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At Biotech Showcase™ 2013

RXi Pharmaceuticals To Present At Biotech Showcase™ 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109

RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109

RXi Pharmaceuticals Corporation (OTC: RXII), today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated.

TheStreet Quant Rating: E+ (Sell)